Sharemaestro Newsreel

T. Rowe Price Associates (NTRA) discloses 9.0M-share Natera stake in updated 13G

T. Rowe Price Associates has reported an updated 6.3% beneficial ownership stake in Natera, Inc. (NTRA) through an amended Schedule 13G filing. The investment firm now holds 9,021,825 shares, with sole voting power over 8,605,302 shares and sole dispositive power over all 9,021,825 shares. …

TuHURA Biosciences Q2 Results: EPS beats estimate, losses narrow 33% YoY

Abbott Laboratories: Revenue and Earnings Analysts Forecasts Revisions | ABT | US0028241000

Promis Neurosciences (NASDAQ:PMN) Stock Price Expected to Rise, Guggenheim Analyst Says

Guggenheim raised its price target for Promis Neurosciences (NASDAQ:PMN) from $69 to $100, maintaining a "Buy" rating, while other analysts have varied ratings but a consensus "Moderate Buy" with a $39.25 target. The clinical-stage biopharmaceutical company's shares opened at $14.93, with a market capitalization …

ProMIS Neurosciences Inc. Stock 12‑Month Price Target Raised to $43.64, Implies 195% Upside

ProMIS Neurosciences Inc. (PMN) has seen its 12-month average price target raised by analysts from $39.21 to $43.64, with forecasts ranging from $18 to $100 per share. This new target suggests a potential upside of approximately 195% based on the August 13 closing price. …

Kodiak's Q2 Loss Wider Than Expected, Pipeline Development in Focus

Kodiak Sciences reported a wider-than-expected Q2 2026 loss of $1.05 per share, surpassing the Zacks Consensus Estimate of a 97-cent loss. Despite increased R&D expenses for pipeline development, the company's cash position is expected to sustain operations into 2027. Kodiak is accelerating regulatory submissions …

Kaplan Fox Alerts Embecta Corp. (NASDAQ: EMBC) Investors Who Suffered Losses to a Securities Class Action – Deadline is August 17, 2026

Kaplan Fox & Kilsheimer LLP has filed a class action lawsuit against Embecta Corp. (NASDAQ: EMBC) on behalf of investors who purchased securities between November 25, 2025, and May 4, 2026. The lawsuit stems from Embecta's Q2 2026 financial results, which were significantly below …

EMBC Shareholder Alert: August 17, 2026 Lead Plaintiff Deadline in Embecta Corp. Securities Class Action - Contact The Gross Law Firm

The Gross Law Firm has issued a shareholder alert regarding a securities class action against Embecta Corp. (NASDAQ: EMBC). Shareholders who purchased EMBC shares between November 25, 2025, and May 4, 2026, are encouraged to contact the firm, as the company is accused of …

ARDX SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Ardelyx

SueWallSt, powered by Levi & Korsinsky LLP, has announced an investigation into potential securities law violations concerning Ardelyx (ARDX). This comes after Ardelyx cut its 2026 IBSRELA revenue guidance by up to $80 million on August 6, 2026, due to payer utilization-management restrictions, causing …

Intelligent Bio Solutions (INBS) gets 5.91% ownership update from Armistice Capital

Armistice Capital, LLC and Steven Boyd have filed an amended passive ownership report for Intelligent Bio Solutions Inc. (INBS), disclosing a beneficial ownership of 141,397 shares, which represents 5.91% of the common stock. All shares are held with shared voting and dispositive power. Armistice …

Citius Oncology (CTOR) investor reports 9.99% beneficial ownership stake

Armistice Capital, LLC and Steven Boyd have reported a beneficial ownership of 9,353,553 shares of Citius Oncology, Inc. common stock, which represents a 9.99% stake in the company. They hold shared voting and dispositive power over these shares, which are directly held by Armistice …

Armistice Capital (VSEE) reports 7.33% beneficial stake in VSee Health

Armistice Capital, LLC and Steven Boyd have reported a beneficial ownership of 7.33% in VSee Health, Inc., totaling 4,079,129 shares of common stock. The filing, a Schedule 13G/A, indicates shared voting and dispositive power over these shares, which are directly held by Armistice Capital …

Armistice Capital (EVGN) discloses 4.99% beneficial stake in Evogene shares

Armistice Capital, LLC and Steven Boyd have reported a 4.99% beneficial ownership stake in Evogene Ltd. (EVGN) through an amended Schedule 13G filing. This amounts to 713,539 ordinary shares, which are directly held by Armistice Capital Master Fund Ltd. The filing clarifies that Armistice …

Caribou Biosciences, Inc. Stock 12‑Month Price Target Cut to $11.86, Implies 636% Upside

Analysts have cut the 12-month average price target for Caribou Biosciences, Inc. stock from $12 to $11.86, with individual forecasts ranging from $4 to $32 per share. Despite the slight reduction in the average target, this still implies a significant 636% potential upside based …

Candel Therapeutics, Inc. Stock 12‑Month Price Target Raised to $20.88, Implies 77% Upside

Candel Therapeutics, Inc. (CADL) has seen its average 12-month price target raised to $20.88 by analysts, up from $20.5, with individual forecasts ranging from $12 to $29. This new target suggests a potential upside of approximately 77% from its closing price on August 13. …

Theravance Biopharma (TBPH) investor group reports 17.7% beneficial stake

An investor group led by Madison Avenue International LP has reported a 17.7% beneficial stake in Theravance Biopharma, Inc. (TBPH) as of June 30, 2026. This ownership, comprising 9,212,252 Ordinary Shares, is based on 51,918,754 outstanding shares as of July 31, 2026. The group, …

T. Rowe Price Associates (EHC) discloses 5.1% Encompass Health stake on Schedule 13G

T. Rowe Price Associates has filed a Schedule 13G, disclosing a 5.1% beneficial ownership stake in Encompass Health Corp (EHC), totaling 5,056,225 common stock shares. The filing indicates that T. Rowe Price Associates holds sole voting power over 4,897,333 shares and sole dispositive power …

T. Rowe Price Associates (CLDX) discloses 6.0% Celldex Therapeutics ownership on Schedule 13G

T. Rowe Price Associates has disclosed a 6.0% beneficial ownership stake in Celldex Therapeutics Inc. (CLDX) through a Schedule 13G filing. The firm reported holding 4,686,187 shares of common stock, with sole voting power over 4,683,226 shares and sole dispositive power over all 4,686,187 …

Alamar Biosciences (ALMR) Stock Price Jumps As Margin Gains Meet Loss Pressure

Alamar Biosciences (ALMR) stock surged 30.7% after its first post-IPO quarter, despite reporting a net loss of US$13.2m. The company achieved US$29.4m in revenue and a record 60% gross margin, driven by strong demand for consumables and instruments. While bulls highlight top-line growth and …

Galectin Therapeutics Releases Q2 2026 Financial Results

Galectin Therapeutics Inc. (GALT) reported a wider net loss of $0.14 per share, or $9.1 million, for Q2 2026, an increase from $0.12 per share in the prior year. This reflects the company's continued investment in developing new drugs for fibrotic disease and cancer …

Skye Bioscience to Acquire Redx; Secures $67.9M Financing and $22M Equity Line

Skye Bioscience is set to acquire Redx through a UK court-sanctioned scheme of arrangement, backed by a significant financing package. The deal includes a $67.9 million equity financing (potentially rising to $72.9 million), a $22.0 million equity line, and a $5.0 million warrant with …

Armistice Capital (IRWD) discloses 13.9M-share Ironwood Pharmaceuticals stake

Armistice Capital, LLC and Steven Boyd have reported a beneficial ownership of 13,932,000 shares of Ironwood Pharmaceuticals, Inc.'s Class A common stock, which represents 8.43% of the outstanding class as of June 30, 2026. This stake is held by Armistice Capital Master Fund Ltd., …

T. Rowe Price discloses 4.9% Guardant Health (GH) holding in 13G/A

T. Rowe Price Associates, Inc. has filed a Schedule 13G/A, disclosing a 4.9% beneficial ownership in Guardant Health, Inc. (GH) as of June 30, 2026. The firm holds 6,514,828 shares, with sole voting power over 6,359,951 shares and sole dispositive power over all 6,514,828 …

RBC Adjusts Price Target on CorMedix to $14 From $13, Maintains Outperform Speculative Risk Rating

RBC Capital Markets has increased its price target for CorMedix (CRMD) to $14 from $13, while reiterating an Outperform Speculative Risk rating. This adjustment reflects a positive outlook on the company's financial prospects and potential market performance.

CRMD Stock Up as Q2 Earnings & Sales Beat on DefenCath, Melinta Gains

CorMedix Therapeutics (CRMD) reported strong Q2 2026 results, with adjusted earnings and consolidated revenues surpassing analyst estimates, primarily driven by strong DefenCath sales and the contribution from the acquired Melinta portfolio. Following these positive results, management raised its full-year EBITDA outlook. The stock saw …

T. Rowe Price Investment Management (STTK) reports 15.3% stake in Shattuck Labs

T. Rowe Price Investment Management, Inc. has reported a 15.3% beneficial ownership stake in Shattuck Labs Inc. (STTK), totaling 13,432,540 shares. This ownership is primarily for its advisory clients, with T. Rowe Price Small-Cap Value Fund holding a significant portion (5.6%). The filing clarifies …

Verastem, Inc. (VSTM) sees 7.76% ownership reported by Armistice Capital

Armistice Capital, LLC and Steven Boyd have reported a significant beneficial ownership stake of 7.76% in Verastem, Inc. (VSTM), totaling 7,024,000 shares. This ownership is held with shared voting and dispositive power through Armistice Capital Master Fund Ltd., where Armistice Capital acts as the …

Dow Movers: AMGN, HONIV

In early trading on Friday, shares of Honeywell International topped the list of the day's best performing Dow Jones Industrial Average components, trading up 7.5%. Year to date, Honeywell International registers a 42.2% gain. And the worst performing Dow component thus far on the …

ImmuCell Q2 Earnings Call Highlights

Key Points Interested in ImmuCell Corporation? Here are five stocks we like better. Strong domestic growth drove results: Second-quarter product sales rose 11.5% year over year to $7.2 million, while net income increased to $1.8 million from $500,000. Domestic sales grew 27.7%, offsetting a …

T. Rowe Price Associates (RNA) discloses 8.6% Atrium Therapeutics ownership in 13G/A

T. Rowe Price Associates, Inc. has filed an amended Schedule 13G, disclosing a beneficial ownership of 1,472,984 shares in Atrium Therapeutics Inc., which constitutes an 8.6% stake in the company. The filing indicates that T. Rowe Price Associates holds sole voting power over 1,472,772 …

Armistice Capital discloses 9.53% CervoMed (CRVO) ownership via Master Fund

Armistice Capital, LLC and Steven Boyd have reported a beneficial ownership of 9.53% in CervoMed Inc. (CRVO), totaling 1,592,863 shares of common stock. These shares are held by Armistice Capital Master Fund Ltd., with Armistice Capital serving as the investment manager, granting them shared …

Zenas BioPharma's (ZBIO) Buy Rating Reaffirmed at Guggenheim

Guggenheim reaffirmed its "buy" rating for Zenas BioPharma (ZBIO) with a $55 price target, despite the company reporting weaker-than-expected quarterly results, including an EPS loss of $1.77 and revenue of $1 million. Analyst sentiment for ZBIO remains generally positive with a "Moderate Buy" consensus …

Armistice Capital discloses 9.99% Co-Diagnostics (CODX) holding via Master Fund

Armistice Capital, LLC and its managing member Steven Boyd have reported a beneficial ownership of 9.99% in Co-Diagnostics (CODX), amounting to 559,706 shares. These shares are held by Armistice Capital Master Fund Ltd., with Armistice Capital serving as the investment manager. The filing indicates …

Baron group trims CareDx (CDNA) stake to 3.75% in latest 13G/A

Baron Capital Group, including its affiliates BAMCO, Inc. and Baron Capital Management, Inc., and Ronald Baron, have filed an amended Schedule 13G for CareDx, Inc. (CDNA), reporting a beneficial ownership of 1,937,326 shares, which represents 3.75% of the company's common stock. This filing indicates …

Estrella Immunopharma (ESLA): Armistice Capital discloses 4.99% ownership stake

Armistice Capital, LLC and Steven Boyd have disclosed a 4.99% beneficial ownership stake in Estrella Immunopharma, Inc. (ESLA) common stock. This translates to 2,051,409 shares, over which they hold shared voting and dispositive power. The shares are held by Armistice Capital Master Fund Ltd., …

Earnings call transcript: Lantern Pharma posts q2 2026 loss miss as stock slips

Lantern Pharma reported a wider-than-expected Q2 2026 net loss of $0.57 per share, primarily due to $3.6 million in non-cash warrant expenses, despite a 25% reduction in operating expenses and significant advancements in its clinical programs. The company also announced the establishment of Open-Medicine …